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a  b  s  t  r  a  c  t
Background:  Although  in the  majority  of cases  dengue  virus  (DENV)  infection  results  in  a  self-limiting
febrile  disease,  it can  cause  severe  plasma  leakage  in  a  minority  of  patients.  The  appearance  of  plasma
leakage  indicates  an  increased  permeability  of  the  vascular  wall.  In this  study  we  investigated  if  DENV
infection  can lead  to  leakage  of lipopolysaccharide  (LPS)  from  the  intestine  into  the  blood of  the patient,
indicative  of  an  increased  permeability  of  the intestinal  mucosal  barrier.
Objectives:  The  aim  of  this  study  was  to investigate  if  LPS  levels  were  elevated  in  DENV  infected  patients
and  if  these  levels  correlated  with  disease  severity.
Study design:  LPS  levels  in the  blood  of  DENV  infected  children  were  determined  using  the  Limulus  Ame-
bocyte  Lysate  assay.  To  determine  disease  severity  we  used  the 1997-WHO  criteria,  the expert  physician’s
judgement  and  a  score  that  focused  on  plasma  leakage  in  particular.  Furthermore,  the  modulatory  fac-
tors  LPS  binding  protein  (LBP)  and  sCD14,  as  well  as  the immune  activation  marker  neopterin  were
determined.
Results:  We  showed  signiﬁcantly  elevated  LPS  levels  in  plasma  of  DENV  infected  children  compared  to
healthy  controls.  The  plasma  leakage  severity  score  had  the  strongest  correlation  with  levels  of  LPS. LBP,
sCD14  and neopterin  were  elevated  compared  to  healthy  controls.
Conclusion:  In  this  study  we  show  evidence  of  elevated  LPS  levels  during  DENV  infection.  Moreover,  a
correlation  between  LPS  levels  and  disease  severity  was  found,  especially  when  disease  severity  was
determined  in  terms  of  plasma  leakage.. Background
Dengue virus (DENV) belongs to the family Flaviviridae and
onsists of four serotypes (DENV 1–4). Annually an estimated
umber of 50–100 million infections occur in tropical and sub-
ropical countries around the world. DENV-infection usually results
n a subclinical or self-limiting febrile disease but may  also
ead to severe disease, previously known as dengue haemor-
hagic fever (DHF) and dengue shock syndrome (DSS). Severe
Abbreviations: DENV, (dengue virus); LPS, (lipopolysaccharide); MT,  (microbial
ranslocation); LBP, (lipopolysaccharide binding protein); sCD14, (soluble CD14);
CD14, (membrane-bound CD14); GALT, (gut-associated lymphoid tissue); HIV,
human immunodeﬁciency virus); DF, (dengue fever); DHF, (dengue haemorrhagic
ever); DSS, (dengue shock syndrome); PLS, (plasma leakage severity); LAL, (Limulus
mebocyte Lysate).
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disease is characterised by thrombocytopenia, haemorrhagic man-
ifestations, liver disturbances and a sudden onset of vascular
permeability, believed to be caused by a cytokine storm (reviewed
in1).
The primary target cells of DENV are monocytes and tis-
sue macrophages. In humans the gut-associated lymphoid tissue
(GALT) contains the largest pool of macrophages and memory
T cells. Another virus that targets mononuclear cells is human
immunodeﬁciency virus (HIV). Recently it was shown that repli-
cation of HIV in the GALT was associated with elevated LPS levels,
also known as microbial translocation (MT).2
MT  and its effects have extensively been studied in diseases
where the intestinal mucosal barrier is severely damaged or
inﬂamed, e.g. in graft vs. host disease after hematopoietic stem
Open access under the Elsevier OA license.cell transplantation3 and inﬂammatory bowel disease.4 In these
diseases it has been found that MT  contributes signiﬁcantly to the
inﬂammatory response. Moreover, it has been shown that in Gram-





































pC.A.M. van de Weg  et al. / Journa
aused by an exaggerated immune response, MT  occurs and corre-
ates with disease severity and clinical outcome.5
Like sepsis, the hallmarks of severe DENV infection are plasma
eakage and a highly activated immune system.1 Moreover, like
IV DENV predominantly replicates in mononuclear cells of which
any reside in the GALT. Taken together, we hypothesize that
ENV-infection may  cause MT  and that LPS levels may  correlate
ith disease severity.
.1. Objectives
The objective of this study was to investigate whether elevated
PS levels can be found in DENV infected patients and whether
hese levels correlate with disease severity.
. Study design
.1. Clinical cohort
Following written parental consent, serial blood samples from
00 children aged 3–14 years with a clinical suspicion on DENV
nfection were collected at the Dr. Kariadi Hospital in Semarang,
ndonesia in the period of February 2001 till March 2003.6 This
tudy was approved by the ethics committee of the Dr. Kariadi
ospital.
DENV infection was  conﬁrmed by serotype-speciﬁc reverse
ranscription-PCR (RT-PCR) from the samples obtained at day of
dmission7 or by detection of DENV speciﬁc IgM antibodies (Focus
echnologies) in acute and/or convalescent samples. Thirty-seven
hildren from the same area who had the same genetic background
ut a negative serology for DENV-infection served as healthy con-
rols.
Patients were classiﬁed using three classiﬁcation systems. The
rst two were the stringent 1997-WHO-criteria8 and the expert
hysician’s judgement of disease severity (MD  classiﬁcation). The
D classiﬁcation is the diagnosis given by the treating physician
nd recorded in the patient’s chart. The possible diagnoses in the
D classiﬁcation are: DF, DHF and DSS – intuitively based on phys-
cal examination, clinical course and laboratory data.
The third classiﬁcation system was based on a plasma leakageeverity (PLS) score that takes the following signs into account:
t > 45.0%, tachycardia (pulse >120/min), hypotension (systolic
lood pressure <80 mmHg), narrow pulse pressure (difference
etween systolic and diastolic blood pressure <20 mmHg), pleural
able 1
atient characteristics of the Indonesian cohort classiﬁed according to the 1997-WHO cri
lasma  leakage severity score are expressed as median (interquartile range).





Sex 50.0% male 51.1% male 
Age  (years) 7.5 (4–11) 8 (5–10) 
Days  of fever 3 (2–3.25) 3 (3–4) 
Haemoglobin (g/dl) 11.8 (10.9–13.1) 13.2 (12.0–14.3
Haematocrit (%) 35.7 (23.1–36.7) 40.9 (36.9–43.6
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effusion (proven by X-ray), and signs of ascites (shown by physi-
cal examination). Each sign present is assigned a value 1; the PLS
score was  deﬁned as the sum of these values, ranging from 0 to 6.
Haemoglobin and haematocrit levels, as well as any signs of plasma
leakage were recorded daily.
2.2. Laboratory determinations
Samples have been stored at −80◦ C and repetitive freeze–thaw
cycles have been avoided. LPS was determined with a commercially
available Limulus Amebocyte Lysate (LAL) assay (Associates of Cape
Cod Incorporated). Because components in plasma may  interfere
with this assay,9 plasma samples were diluted 1:5 with LAL reagent
water and heat-inactivated at 60 ◦C for 30 min. Known concen-
trations of Escherichia coli LPS were diluted in heat-inactivated
negative plasma (1:5 dilution) and served as standard values. The
standard and plasma samples were incubated with the pyrochrome
for 70 min  at 37 ◦C. After the reaction was  stopped the test was  read
at an absorbence of 405 nm.
Soluble CD14 (sCD14; ‘Quantikine’ ELISA, R&D Systems), LPS
binding protein (LBP; HK315′ ELISA, Hycult Biotech), and neopterin
(IBL ImmunoBiological Laboratories) were determined using com-
mercially available assays. To this end, samples were diluted 1:200
(sCD14), 1:1000 (LBP), and used undiluted (neopterin). The assays
were performed according to the manufacturer’s instructions.
2.3. Statistical analysis
The Kruskal Wallis H test was used for comparison of more than
two  groups. Statistical signiﬁcance between individual groups was
determined with the Mann Whitney U test. Correlations between
continuous variables were determined with the Spearman correla-
tion coefﬁcient test. P values ≤0.05 were considered signiﬁcant.
3. Results
Eighty-nine plasma samples from Indonesian children with lab-
oratory conﬁrmed DENV infection were selected for this analysis.
Clinical characteristics of the cohort are summarized in Table 1.
Based on the MD  classiﬁcation, more patients had severe disease
(DHF/DSS) than those diagnosed with the 1997-WHO classiﬁcation
(Table 1). The application of the PLS score to both classiﬁcations
supported the MD  classiﬁcation of disease severity. The median PLS
score of patients classiﬁed with DF, DHF and DSS according to the










46.2% male 50.0% male 48.6% male 50.0% male
7 (5–10) 8 (6.25–11.5) 8 (6–10) 7 (5–10)
4 (3.75–5) 3 (2–4) 4 (3–4) 4 (3–4)
) 14.1 (12.2–14.9) 11.9 (11.4–13.1) 12.9 (12.0–13.9) 13.8 (11.9–15.1)









































2 (2–3.25) 0 (0–0.25) 1 (0–1) 2 (2–3)
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HO  system was 1, 1, and 2 respectively. In contrast, the median
LS score in the MD  classiﬁcation for DF, DHF, and DSS was 0, 1 and 2
espectively. It has been reported previously10 that due to the strin-
ency of the 1997-WHO classiﬁcation patients with severe disease
ccording to the expert physician’s judgement may  be classiﬁed as
aving non-severe disease (Table 1).
To investigate whether MT  occurred during DENV infections,
PS levels were measured. Signiﬁcantly elevated LPS levels were
etected in the plasma of all DENV infected patients compared to
ealthy controls (Fig. 1A–C). LPS levels were subsequently analyzed
n relation to disease severity. Using the 1997-WHO classiﬁca-
ion only a signiﬁcant difference was found between DHF and
SS patients (P = 0.04) (Fig. 1A). However, when patients were
ivided according to the MD classiﬁcation, LPS levels in patients
ith DSS differed signiﬁcantly from those with DHF (P < 0.001) and
F (P = 0.01).
When plasma LPS levels were compared in patients classiﬁed
ccording to the PLS score, a signiﬁcant difference was  observed
ig. 1. LPS, LBP, sCD14 and neopterin in relation to severity of disease. (A) Correlation b
ifferences were found for DHF vs. DSS (P = 0.04); DF, DHF and DSS vs. healthy controls (H
n  MD classiﬁcation. Signiﬁcant differences for DF vs. DSS (P = 0.01); DHF vs. DSS (P = 0.00
PS  levels and severity of disease based on plasma leakage severity (PLS) score. Signiﬁcant
etween LBP levels and severity of disease based on PLS score. Signiﬁcant differences for 0
evels  and severity of disease based on PLS score. Signiﬁcant differences for 0 vs. ≥3 (P =
everity of disease based on PLS score. Signiﬁcant differences for 0 vs. HC (P = 0.001); 1–2 
roups. means signiﬁcant difference between two groups.*/* means that this group nical Virology 53 (2012) 38– 42
between the group with no signs and the groups with three and
more signs (P = 0.006) (Fig. 1C). A trend was  shown in which a higher
PLS score correlated with increased LPS levels.
As LBP and sCD14 play an important role in the modulation of the
LPS response we  measured their levels in relation to the PLS score.
As shown in Fig. 1D, the LBP-levels in the group with three and more
symptoms were signiﬁcantly lower than the levels in groups with
no symptoms (P = 0.002). The levels of the healthy controls were
signiﬁcantly lower than in all other groups (P < 0.0001). Similarly,
the levels of sCD14 in the group with three and more symptoms
were slightly lower than the group with no symptoms (P = 0.046)
(Fig. 1E). The levels in all groups were elevated compared to the
healthy controls (P < 0.001).
To investigate whether MT  was  associated with activa-
tion of monocytes/macrophages the levels of neopterin were
determined. The elevated neopterin levels indicated that mono-
cytes/macrophages were signiﬁcantly activated in DENV infected
patients compared to healthy controls (P ≤ 0.01). Consistently, a
etween LPS levels and severity of disease based on 1997-WHO criteria. Signiﬁcant
C) (all P < 0.0001). (B) Correlation between LPS levels and severity of disease based
01); DF vs. HC (P = 0.003); DHF and DSS vs. HC (P < 0.0001). (C) Correlation between
 differences for 0 vs. ≥3 (P = 0.006); 0, 1–2 and ≥3 vs. HC (P < 0.0001). (D) Correlation
 vs. ≥3 (P = 0.002); 0, 1–2 and ≥3 vs. HC (P < 0.0001). (E) Correlation between sCD14
 0.046); 0, 1–2 and ≥3 vs. HC (P < 0.0001). (F) Correlation between neopterin and
vs. HC (P = 0.003); ≥3 vs. HC (P = 0.001). Horizontal lines indicate the median of the
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eak correlation between levels of LPS and levels of neopterin
as observed (P = 0.023, r = 0.29) (data not shown). Moreover, there
as a slightly stronger correlation between LBP and sCD14-levels
P = 0.0002, r = 0.40) (data not shown).
. Discussion
In this study we found elevated levels of LPS in DENV-infected
atients compared to healthy controls. Moreover, the levels of LPS
howed to have a correlation with disease severity, indicated by an
ncreased PLS score.
Classifying DENV-infected patient in terms of disease severity
as always been a challenge to physicians and researchers in the
eld. The application of our PLS score to the 1997-WHO classiﬁca-
ion and the MD  classiﬁcation suggests that the MD  classiﬁcation
eﬂects disease severity more accurately.
Plasma leakage is a hallmark of severe DENV-infection and may
e indicative of increased permeability of the vascular wall. There-
ore we hypothesized that a similar mechanism causing plasma
eakage may  be in part responsible for MT.  In agreement with this
he PLS score showed the best correlation with LPS levels com-
ared with the 1997-WHO and MD-classiﬁcation. However, the PLS
core only accounts for plasma leakage and shock, while haemor-
hagic, gastrointestinal and liver manifestations are not taken into
ccount. Nevertheless, LPS levels did not correlate with the occur-
ence of haemorrhage and the levels of liver enzymes (data not
hown). From the gastrointestinal manifestations diarrhea is most
ikely to be associated with MT.  However, only four patients were
eported to suffer from diarrhea in our study population.
Taken together, our data suggest that in order to investigate
ertain speciﬁc pathogenetic pathways in humans it might be use-
ul to classify patients according to speciﬁc clinical symptoms and
aboratory markers.
Because of the interference with plasma components the LAL
ssay is known to be very challenging and therefore several strate-
ies have been described.9 Interestingly, the absolute values of LPS
n our study were higher compared to those reported in other
tudies.2,4,5 The difference between this study and others is that
he standard was diluted in a plasma dilution comparable with the
ilution of the patient samples. Because of the inhibitory activity
f plasma the standard should contain the same amount of plasma
s the diluted samples.
LPS is an important immune stimulator, because it can activate
he innate immune system by signalling through a membrane-
ound CD14(mCD14)/Toll-like receptor 4 complex. The systemic
esponse upon the release of LPS in the circulation is modulated
y LBP and sCD14. LBP is synthesized by the liver upon stimulation
ith LPS and can accelerate the transfer of LPS to membrane-bound
D14. On the other hand LBP can also shuttle LPS to lipoproteins.11
he LBP concentrations in patients with a PLS score ≥3 were very
ow, suggesting that severely ill patients fail to produce enough LBP
o neutralize LPS. These results are comparable with those from
tudies about MT  and septic shock, in which non-survivors had
ower LBP values than survivors.5
sCD14 is produced by monocytes upon activation by LPS and
as been suggested as a marker for disease severity.12 In our study
opulation the levels of sCD14 were signiﬁcantly elevated in all
roups compared to healthy controls. Moreover, the group with
he highest PLS score also showed decreased levels of sCD14, but
o a lesser extent than the LBP levels. This was  also found in
atients with sepsis.13 A dual mechanism may  be involved here.
n the one hand, high concentrations of sCD14 prevent an exag-
erated immune response by competing with LPS for mCD14. On
he other hand, low amounts of sCD14-LPS complexes can activate
ndothelial cells.14inical Virology 53 (2012) 38– 42 41
In HIV infected individuals MT  has also been found and shown to
correlate with the activity of the disease.2 During active HIV disease
infection and depletion of CD4 + T cells contributes signiﬁcantly to
disease pathogenesis. A substantial part of these CD4 + T cells reside
in the GALT and therefore the GALT is probably highly affected in
these individuals, which eventually can result in impaired mucosal
integrity.15 It is not clear whether DENV replicates in cells of
the GALT. However, it is likely because intestinal macrophages
represent the largest pool of tissue macrophages in humans. We
hypothesize that DENV replication in intestinal macrophages may
lead to a pro-inﬂammatory environment in which the epithelial
cells are disrupted. In agreement with other studies16,17 we found
increased levels of neopterin in DENV-infected patients indicative
of monocyte activation.
Taken together, this is the ﬁrst study suggesting that DENV infec-
tion may  be associated with MT,  as measured by plasma levels of
LPS. Furthermore, levels of LPS seemed to correlate with disease
severity. Further studies are needed to elucidate the implications
of this ﬁnding.
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